Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow MYGN by emailGet an email when MYGN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MYGN, unsubscribe in one click. Privacy
📣 What MYGN Says Is Next
in 2026 · ““Our limited launch of Precise MRD for breast cancer patients has received positive early feedback and we remain on track with our other planned launches in 2026, as part of our milestone-rich year.”
Company press release, May 5, 2026 · SEC filing
fourth quarter · “The company plans to release its actual financial results for the fourth quarter and full year 2025 during its earnings call to be held in February 2026.”
Company press release, Jan 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full MYGN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MYGN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.